Recombinant Technologies LLC
Medtech · Private
Amytrapper Catheter: an extracorporeal apheresis device coated with a tetrameric retro-inverso peptide (Amytrap) that binds and removes circulating amyloid-beta from blood to treat Alzheimer's disease
recombtech.com →- Grants
- $7.0M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Small Molecule Therapy For Alzheimer's Disease | $519,209 | |
| Federal grant | Department of Health and Human Services · Phase II · Small Molecule Therapy For Alzheimer's Disease | $1,696,216 | |
| Federal grant | Department of Health and Human Services · Phase II · Small Molecule Therapy For Alzheimer's Disease | $519,209 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel extracorporeal device 'Amytrapper' to remove beta amyloid in Alzheimer's Disease. | $148,491 | |
| Federal grant | Department of Health and Human Services · Phase II · Small molecule therapy for Alzheimer's Disease | $138,589 | |
| Federal grant | Department of Health and Human Services · Phase II · Small Molecule Therapy For Alzheimer's Disease | $519,209 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer's Disease | $474,821 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer's Disease | $164,780 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer's Disease | $592,009 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease | $806,673 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease | $784,203 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease | $625,405 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1793 | NEURALTRAK, INC | — | — |
| 1794 | Atocera, Inc. | — | — |
| 1795 | MDDX, INC. | — | — |
| 1796 | Recombinant Technologies LLC | — | — |
| 1797 | GAIA MEDICAL INSTITUTE, LLC, THE | — | — |
| 1798 | PRECISION MEMBRANES, LLC | — | — |
| 1799 | LED RADIOFLUIDICS CORP | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions Comprising Capture Peptides For A ¿-amyloid Peptideapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.